Market Overview:
The global upper respiratory tract infection treatment market is expected to grow at a CAGR of 5.5% from 2018 to 2030. The growth in the market can be attributed to the increasing incidence of respiratory infections, rising awareness about available treatments, and growing demand for advanced therapies. The global upper respiratory tract infection treatment market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into antibiotics, nonsteroidal anti-inflammatory drugs (NSAIDs), and nasal decongestants. The antibiotics segment accounted for the largest share of the global upper respiratory tract infection treatment market in 2017 owing to their high efficacy in treating various types of infections. However, this segment is expected to lose its share over the forecast period due to growing resistance against antibiotics by microorganisms.
Product Definition:
Upper respiratory tract infection treatment is the use of medication to help cure or lessen the symptoms of an upper respiratory infection. Upper respiratory infections are a common type of illness, and can be caused by a variety of viruses or bacteria. The most common symptoms include fever, headache, sore throat, and runny nose. Treatment for an upper respiratory infection typically includes antibiotics if the infection is caused by a bacterial pathogen, as well as medications to help relieve symptoms such as fever and pain. Upper respiratory tract infections can often be prevented through good hygiene habits and prompt treatment of any underlying health conditions that may predispose someone to developing an infection.
Antibiotics:
Antibiotics Market Size, Share & Trends Analysis Report By Product (Penicillin, Cephalosporin), By Application (Upper Respiratory Tract Infection Treatment), And Segment Forecasts, 2019 - 2026 -> The global antibiotics market size was valued at USD 19.1 billion in 2018 and is expected to grow at a compound annual growth rate (CAGR) of 3.8% from 2019 to 2026.
Nonsteroidal Anti-inflammatory Drugs (NSAIDs) and Nasal Decongestants:
Nonsteroidal anti-inflammatory drugs (NSAIDs) and nasal decongestants are used in the treatment of upper respiratory tract infection. The global Nasal Decongestant Market is expected to witness significant growth over the forecast period owing to rising prevalence of sinusitis, cold & flu viruses, allergies, and other infections.
Application Insights:
The other application segment of the global upper respiratory tract infection (URT) treatment market includes symptoms other than those mentioned above. The segment is categorized into allergic rhinitis, laryngitis, sinusitis, and others. allergic rhinitis is expected to be the fastest-growing segment over the forecast period due to increasing awareness about its treatment and availability of effective drugs in the market.
Upper respiratory tract infections (URTIs) are highly prevalent diseases that affect people across all age groups and genders. According to a study published in NCBI, it was found that URTIs were more common among women as compared men owing to factors such as hygiene habits different between sexes or because of biological differences between them such as exposure frequency towards URTIs etc., which causes inflammation inside nose & throat area leading to nasal congestion & fever etc., respectively.
Regional Analysis:
North America dominated the global upper respiratory tract infection treatment market in 2017. The rising prevalence of rhinitis, sinusitis, and other upper respiratory infections is one of the major factors contributing to market growth. According to a study published by National Center for Health Statistics (NCHS), in U.S., around 16% population had suffered from sinusitis or rhinitis during the year 2000; this number increased to 26% between 2010 and 2014.
Growth Factors:
- Increasing incidence of respiratory tract infections
- Growing awareness about the benefits of early treatment
- Rising demand for convenient and easy-to-use treatment options
- Technological advancements in respiratory tract infection treatment therapies
- increasing healthcare expenditure
Scope Of The Report
Report Attributes
Report Details
Report Title
Upper Respiratory Tract Infection Treatment Market Research Report
By Type
Antibiotics, Nonsteroidal Anti-inflammatory Drugs (NSAIDs) and Nasal Decongestants, Others
By Application
Rhinitis, Sinusitis, Nasopharyngitis, Epiglottitis, Laryngitis, Whooping Cough, Others
By Companies
GlaxoSmithKline Plc, Merck & Co., Inc., Pfizer Inc., Regeneron Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd.
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
133
Number of Tables & Figures
94
Customization Available
Yes, the report can be customized as per your need.
Global Upper Respiratory Tract Infection Treatment Market Report Segments:
The global Upper Respiratory Tract Infection Treatment market is segmented on the basis of:
Types
Antibiotics, Nonsteroidal Anti-inflammatory Drugs (NSAIDs) and Nasal Decongestants, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Rhinitis, Sinusitis, Nasopharyngitis, Epiglottitis, Laryngitis, Whooping Cough, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- GlaxoSmithKline Plc
- Merck & Co., Inc.
- Pfizer Inc.
- Regeneron Pharmaceuticals Inc.
- Teva Pharmaceutical Industries Ltd.
Highlights of The Upper Respiratory Tract Infection Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Antibiotics
- Nonsteroidal Anti-inflammatory Drugs (NSAIDs) and Nasal Decongestants
- Others
- By Application:
- Rhinitis
- Sinusitis
- Nasopharyngitis
- Epiglottitis
- Laryngitis
- Whooping Cough
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Upper Respiratory Tract Infection Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
There is no one-size-fits-all answer to this question, as the best treatment for an Upper Respiratory Tract Infection will vary depending on the individual's symptoms and health history. However, some general tips that may help treat an Upper Respiratory Tract Infection include: taking antibiotics prescribed by a doctor, drinking plenty of fluids and avoiding strenuous activity.
Some of the key players operating in the upper respiratory tract infection treatment market are GlaxoSmithKline Plc, Merck & Co., Inc., Pfizer Inc., Regeneron Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd..
The upper respiratory tract infection treatment market is expected to grow at a compound annual growth rate of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Upper Respiratory Tract Infection Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Upper Respiratory Tract Infection Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Upper Respiratory Tract Infection Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Upper Respiratory Tract Infection Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Upper Respiratory Tract Infection Treatment Market Size & Forecast, 2018-2028
4.5.1 Upper Respiratory Tract Infection Treatment Market Size and Y-o-Y Growth
4.5.2 Upper Respiratory Tract Infection Treatment Market Absolute $ Opportunity
Chapter 5 Global Upper Respiratory Tract Infection Treatment Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Upper Respiratory Tract Infection Treatment Market Size Forecast by Type
5.2.1 Antibiotics
5.2.2 Nonsteroidal Anti-inflammatory Drugs (NSAIDs) and Nasal Decongestants
5.2.3 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Upper Respiratory Tract Infection Treatment Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Upper Respiratory Tract Infection Treatment Market Size Forecast by Applications
6.2.1 Rhinitis
6.2.2 Sinusitis
6.2.3 Nasopharyngitis
6.2.4 Epiglottitis
6.2.5 Laryngitis
6.2.6 Whooping Cough
6.2.7 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Upper Respiratory Tract Infection Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Upper Respiratory Tract Infection Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Upper Respiratory Tract Infection Treatment Analysis and Forecast
9.1 Introduction
9.2 North America Upper Respiratory Tract Infection Treatment Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Upper Respiratory Tract Infection Treatment Market Size Forecast by Type
9.6.1 Antibiotics
9.6.2 Nonsteroidal Anti-inflammatory Drugs (NSAIDs) and Nasal Decongestants
9.6.3 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Upper Respiratory Tract Infection Treatment Market Size Forecast by Applications
9.10.1 Rhinitis
9.10.2 Sinusitis
9.10.3 Nasopharyngitis
9.10.4 Epiglottitis
9.10.5 Laryngitis
9.10.6 Whooping Cough
9.10.7 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Upper Respiratory Tract Infection Treatment Analysis and Forecast
10.1 Introduction
10.2 Europe Upper Respiratory Tract Infection Treatment Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Upper Respiratory Tract Infection Treatment Market Size Forecast by Type
10.6.1 Antibiotics
10.6.2 Nonsteroidal Anti-inflammatory Drugs (NSAIDs) and Nasal Decongestants
10.6.3 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Upper Respiratory Tract Infection Treatment Market Size Forecast by Applications
10.10.1 Rhinitis
10.10.2 Sinusitis
10.10.3 Nasopharyngitis
10.10.4 Epiglottitis
10.10.5 Laryngitis
10.10.6 Whooping Cough
10.10.7 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Upper Respiratory Tract Infection Treatment Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Upper Respiratory Tract Infection Treatment Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Upper Respiratory Tract Infection Treatment Market Size Forecast by Type
11.6.1 Antibiotics
11.6.2 Nonsteroidal Anti-inflammatory Drugs (NSAIDs) and Nasal Decongestants
11.6.3 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Upper Respiratory Tract Infection Treatment Market Size Forecast by Applications
11.10.1 Rhinitis
11.10.2 Sinusitis
11.10.3 Nasopharyngitis
11.10.4 Epiglottitis
11.10.5 Laryngitis
11.10.6 Whooping Cough
11.10.7 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Upper Respiratory Tract Infection Treatment Analysis and Forecast
12.1 Introduction
12.2 Latin America Upper Respiratory Tract Infection Treatment Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Upper Respiratory Tract Infection Treatment Market Size Forecast by Type
12.6.1 Antibiotics
12.6.2 Nonsteroidal Anti-inflammatory Drugs (NSAIDs) and Nasal Decongestants
12.6.3 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Upper Respiratory Tract Infection Treatment Market Size Forecast by Applications
12.10.1 Rhinitis
12.10.2 Sinusitis
12.10.3 Nasopharyngitis
12.10.4 Epiglottitis
12.10.5 Laryngitis
12.10.6 Whooping Cough
12.10.7 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Upper Respiratory Tract Infection Treatment Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Upper Respiratory Tract Infection Treatment Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Upper Respiratory Tract Infection Treatment Market Size Forecast by Type
13.6.1 Antibiotics
13.6.2 Nonsteroidal Anti-inflammatory Drugs (NSAIDs) and Nasal Decongestants
13.6.3 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Upper Respiratory Tract Infection Treatment Market Size Forecast by Applications
13.10.1 Rhinitis
13.10.2 Sinusitis
13.10.3 Nasopharyngitis
13.10.4 Epiglottitis
13.10.5 Laryngitis
13.10.6 Whooping Cough
13.10.7 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Upper Respiratory Tract Infection Treatment Market: Competitive Dashboard
14.2 Global Upper Respiratory Tract Infection Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 GlaxoSmithKline Plc
14.3.2 Merck & Co., Inc.
14.3.3 Pfizer Inc.
14.3.4 Regeneron Pharmaceuticals Inc.
14.3.5 Teva Pharmaceutical Industries Ltd.
